ISODIOL INTERNATIONAL INC. SIGNS DEFINITIVE LICENSING AGREEMENT WITH CANOPY GROWTH CORPORATION
2017年7月20日 - 10:28PM
InvestorsHub NewsWire
ISODIOL INTERNATIONAL INC. SIGNS DEFINITIVE LICENSING
AGREEMENT WITH CANOPY GROWTH CORPORATION FOR CANADIAN AND
INTERNATIONAL DISTRIBUTION
July 20, 2017 - Vancouver, BC Isodiol
International Inc. (CSE: ISOL) (OTC: LAGBF) (Frankfurt: LB6A.F)
(the Company or Isodiol) a global cannabis innovator
specializing in the development of pharmaceutical and consumer
products is pleased to announce it has signed a licensing agreement
with Canopy Growth Corporation (Canopy) (TSX:WEED) (https://www.canopygrowth.com).
Canopy Growth is the worlds premier
cannabis company that operates a collection of diverse brands and
curated strain varieties, supported by over half a million square
feet of indoor and greenhouse production capacity. Under this
licensing agreement, Canopy Growth will have the right to
manufacture and distribute the Company's "Pot-O-Coffee" and
"Pot-O-Tea" branded marijuana infused single serve K-Cup products
in Canada and certain other markets internationally as federal
regulations allow. Licensed products include caffeinated and
de-caffinated product lines as well as Isodiol's single serve
"Pot-O-Coco". In addition to the Canadian rights, Canopy Growth
shall have the right of first refusal to sell the "Pot-O" brand
products in any territory outside of the US, Mexico and Puerto
Rico.
This distribution agreement has us
positioned to increase our global footprint with the largest
cannabis company in the world. We will continue to develop our
Pot-O-Coffee product lines with ready to drink and cold brew
products while working with Canopy Growth for international
distribution channels. The Pot-O-Coffee brand is well recognized,
and adding additional products to this line will continue to
strengthen its market presence," stated Isodiol's CEO Marcos
Agramont.
The availability of the various licensed
products in Canada and elsewhere will differ depending on
applicable laws and regulation. While Canadian law does not yet
permit the manufacture and sale of marijuana infused products, the
Company anticipates that such products will be permitted in the
near future. Furthermore, currently proposed regulations which
would permit the sale of infused products, would not allow such
products to contain both marijuana and caffeine. As such, the
specific product offerings in Canada and elsewhere may be limited.
The Company will provide additional updates as regulations are
adopted and as product roll-out plans are developed.
About Isodiol International Inc.
Isodiol International, Inc. is the
market leader in pharmaceutical grade cannabis compounds and the
industry leader in manufacturing and development of consumer
products. Isodiol's nutraceutical division is the pioneer of many
firsts for Hemp-derived cannabidiol (CBD), including 99% pure
crystalline isolate, micro-encapsulation, and nano technology for
the highest quality consumable and topical skin care
products.
Isodiol's growth strategy includes the development of
over-the-counter and pharmaceutical drugs, seeking joint
ventures and acquisitions to expand its portfolio of brands and
subsidiaries and will aggressively continue International expansion
into Latin America, Asia and Europe.
ON BEHALF OF
THE BOARD : “Marcos
Agramont” CEO &
Director
CORPORATE
MEDIA: ir@isodiol.com
www.isodiol.com
Join Us On
Face Book: https://www.facebook.com/isodiol/
Twitter:
@isodiol
Forward-Looking Information: This news release
contains "forward-looking information" within the meaning of
applicable securities laws relating to statements regarding the
Company's business, products and future the Companys business, its
product offerings and plans for sales and marketing. Although the
Company believes that the expectations reflected in the forward
looking information are reasonable, there can be no assurance that
such expectations will prove to be correct. Readers are cautioned
to not place undue reliance on forward-looking information. Such
forward looking statements are subject to risks and uncertainties
that may cause actual results, performance and developments to
differ materially from those contemplated by these statements
depending on, among other things, the risks that the Company's
products and plan will vary from those stated in this news release
and the Company may not be able to carry out its business plans as
expected. Except as required by law, the Company expressly
disclaims any obligation, and does not intend, to update any
forward looking statements or forward-looking information in this
news release. Although the Company believes that the expectations
reflected in the forward looking information are reasonable, there
can be no assurance that such expectations will prove to be correct
and makes no reference to profitability based on sales reported.
The statements in this news release are made as of the date of this
release.
The CSE has not reviewed, approved or
disapproved the content of this press release.
Isodiol (CSE:ISOL)
過去 株価チャート
から 11 2024 まで 12 2024
Isodiol (CSE:ISOL)
過去 株価チャート
から 12 2023 まで 12 2024